Background. Klebsiella pneumoniae causing community-acquired pyogenic liver abscess complicated with metastatic meningitis and endophthalmitis has emerged recently, most frequently associated with the K1 capsular type.
Recently, community-acquired pyogenic liver abscess (PLA) caused by Klebsiella pneumoniae complicated with metastatic meningitis and endophthalmitis has emerged globally, especially in Asia [1] [2] [3] [4] [5] [6] [7] [8] . Besides causing PLA, K. pneumoniae also has been reported to cause invasive infections leading to abscesses at other sites (eg, kidney, spleen, brain, and prostate), necrotizing fasciitis, and severe pneumonia with bacteremia [9] [10] [11] [12] .
Researcher in Taiwan reported that the most common capsular type of the strains causing liver abscess was K1 (63.4%) [13] . The virulence gene magA was shown to be associated with mucoviscosity, resistance to serum and phagocyte killing, and virulence in mice [14] . The magA-containing region was identified to be responsible for the production of capsular type K1 [15] . The identification of magA provided a genetic marker for the K1 type and permitted the development of a capsular polysaccharide (CPS) synthesis region polymerase chain reaction (PCR) genotyping method for capsular typing. Subsequent reports of capsular types in K. pneumoniae causing PLA continue to increase [3, [16] [17] [18] [19] .
Earlier work [20] has demonstrated that 83.3% of 42 K. pneumoniae strains causing PLA belonged to capsular type K1. Similarly, the predominant (52%) capsular type of 50 liver abscess isolates from Southern Taiwan was K1 [21] . In a nationwide study in Korea, 59.4% of K. pneumoniae strains (n = 160) causing PLA belonged to K1 [3] . Moreover, the majority of case reports worldwide revealed that patients with PLA harbored K. pneumoniae K1 strains [10, 16, 18] . In addition to these studies of PLA, a recent study in Taiwan demonstrated that the predominant capsular type of K. pneumoniae strains causing necrotizing fasciitis (4 of 15 strains; 26.7%) also was capsular type K1 [9] . Therefore, the K1 capsular type has been strongly associated with K. pneumoniae causing invasive infections.
We report here the isolation of a bacteriophage specific to capsular type K1 of K. pneumoniae. In this study, the host spectrum, complete genome sequence, and application in diagnosis and treatment of this phage are demonstrated.
MATERIALS AND METHODS

Phage Isolation
Phage infecting K. pneumoniae NTUH-K2044 strain were isolated from untreated water. An agar overlay method was used to isolate a pure phage preparation and determine the titer of the phage [22, 23] .
Host Spectrum Determination
The host spectra of the phage were determined using a spot test. The dilutions of phages were spotted on the LB agar plates overlaid with top agar containing each of the different K. pneumoniae strains (Supplementary Table 1) . A clear spot indicated that the phage could infect the bacterial strain. An efficiency of plating assay was also used to quantify the ability of phage to infect other strains, as described elsewhere [23] . The P value of comparisons of phage infectivity was derived from the generalized linear model and generalized estimating equations (GLM/GEE) with an exchangeable working correlation matrix [24] ; this was carried out using the procedure PROC GENMOD with the SAS statistical package (version 9.2 for Windows; SAS Institute).
Analysis of Bacterial Capsular Polysaccharide
The bacterial extracellular polysaccharide was extracted and then quantified as described elsewhere [25] .
Phage Genomic DNA Preparation and Sequencing
Phage genomic DNA was extracted using Qiagen Lambda kit with modifications as follows. After phages were precipitated and lysed, the DNA was extracted by phenol/chloroform and precipitated with ethanol. The genome sequences of the phage were determined by Illumina GAII sequencing. The 2 ends were completed by walking sequencing. The complete genome sequences were deposited to GenBank (accession No. AB716666).
Protein Expression and Purification
The K1-orf34 was amplified by PCR using primers K1-orf34 + 2-F (5′-CAATGGCATTAATTAGATTAG-3′) and K1-orf34 + 2-R (5′-GAGAGATATACCTCCCAGGCC-3′) and then cloned into pGEM-T Easy Vector Systems (Promega). The resulting plasmid was digested with NotI and the K1-orf34 fragment was cloned into the NotI site of a pET28c plasmid (Novagen). The resulted K1-orf34-pET28c plasmid was transformed into Escherichia coli BL21 (DE3). The recombinant His-tagged K1-ORF34 protein was expressed by induction with 0.1 mmol/L Isopropyl β-D-1-thiogalactopyranoside for 4 hours at 25°C and was purified according to the manufacturer's protocol (Qiagen).
Responses of Phage Inoculation in Mice
The phage solution was purified by using the EndoTrap Red kit (Hyglos) to decrease contamination by bacterial endotoxin. The phage was inoculated intraperitoneally into 15 5-week-old female BALB/cByl mice at a dose of 1 × 10 8 plaque-forming units (PFUs) per mouse. The levels of liver and spleen interleukin 6 (IL-6) and tumor necrosis factor (TNF) α messenger RNA (mRNA) expression in mice before phage inoculation and at 1, 3, 6, and 24 hours after phage inoculation were measured with quantitative reverse-transcription PCR using an ABI 7900 system (Applied Biosystems). The primers for IL-6 (5′-CCACGG CCTTCCCTACTTC-3′ and 5′-TTGGGAGTGGTATCCTCTG TGA-3′), TNF-α (5′-GACGTGGAACTGGCAGAAGAG-3′ and 5′-ACCGCCTGGAGTTCTGGAA-3′), and housekeeping Glyceraldehyde 3-phosphate dehydrogenase control (5′-CAT GGCCTTCCGTGTTCCTA-3′ and 5′-GCGGCACGTCAGAT CCA-3′) were used. CFUs). After 30 minutes of K. pneumoniae infection, the mice were inoculated intraperitoneally with 25 µg of K1-ORF34 protein (4 mice) or not inoculated (8 mice). Survival was analyzed as already described. K1-ORF34 protein treatment for NTUH-K2044 infection (1.6 × 10 3 CFUs) was also performed in mice treated with cyclophosphamide, an immunosuppressive agent (100 mg/kg, 5 days before infection) [26] .
Phage Killing Assay
The bacteria (1 × 10 4 CFUs) were incubated with the NTUH-K2044-K1-1 phage (1 × 10 7 PFUs) at 37°C for 30 minutes.
Then bacterial counts were determined by plating after serial dilutions, and the survival ratio was calculated.
Serum Sensitivity Assay
A total of 1 × 10 4 CFUs bacteria or bacteria pretreated with the K1-ORF34 protein (final concentration, 100 µg/mL) or bacteria pretreated with the K1-ORF34 protein and K1 CPS (final concentration, 5 mg/mL) for 1 hour in 25 µL of normal saline were Figure 1 . A, Plaque shape of the phage NTUH-K2044-K1-1. The clear plaques surrounding with translucent halos were observed on the plate with phage filtrate incubated with Klebsiella pneumoniae NTUH-K2044 strain. B, Infectivity of the phage NTUH-K2044-K1-1 among different capsular type K1 strains. The infectivity of phage NTUH-K2044-K1-1 to 5 strains isolated from patients with pyogenic liver abscess (PLA) (NTUH-K2044, Canada PLA, A8126, 18, and 20) was significantly higher than that to 4 strains collected from the American Type Culture Collection (ATCC) (ATCC8045, ATCC35593, ATCC8047, and A5054) (P < .001; generalized linear model and generalized estimating equations [GLM/GEE] test). The infectivity was represented by the efficiency of plating (log 10 ) from 3 independent experiments (mean ± standard deviation [SD]). C, CPS expression among different capsular type K1 strains. The CPS production of K. pneumoniae strains with PLA (NTUH-K2044, Canada PLA, A8126, 18, and 20) was not significantly higher than that of 4 strains collected from the ATCC (ATCC8045, ATCC35593, ATCC8047, and A5054) (P = .348; GLM/GEE test). The amount of CPS was represented by the optical density at 520 nm (OD 520 ) from 3 independent experiments (mean ± SD).
mixed with 75 µL serum from healthy human volunteers. The mixture was incubated at 37°C for 3 hours. The bacterial counts were then determined, and the survival ratio was calculated.
RESULTS
Isolation of Phage Infecting the K. pneumoniae NTUH-K2044 Strain
The K. pneumoniae NTUH-K2044 (capsular type K1) strain was cocultured with untreated water in LB broth overnight. Plaques were observed after the cocultured filtrates were incubated with the NTUH-K2044 strain ( Figure 1A ). The phage was detected as clear plaques with translucent halos and was designated NTUH-K2044-K1-1.
Host Spectrum of the Bacteriophage NTUH-K2044-K1-1
Findings of previous studies have indicated that the translucent halos surrounding plaques resulted from the capsule-degrading enzymes of phage [27] . Therefore, based on the observed plaque shape of NTUH-K2044-K1-1 phage, we inferred that infection by this phage might correlate with bacterial capsular type. As a first test of the hypothesis, we assessed infection by phage NTUH-K2044-K1-1 on the 78 capsular type reference strains and a KN1 capsular type reference strain, A1517. Spot tests revealed that the phage infected the reference strain with K1 capsular type but not any of the remaining 77 capsular types. Next, the sensitivity for capsular type K1 of NTUH-K2044-K1-1 phage was evaluated among 21 capsular type K1 strains whose capsular type was determined by PCR using wzy primers. This phage could infect all strains with capsular type K1. The infectivity of phage NTUH-K2044-K1-1 was compared among different capsular type K1 strains ( Figure 1B) . The infectivity of phage NTUH-K2044-K1-1 to 5 strains isolated from patients with PLA was significantly higher than that to 4 strains collected from the American Type Culture Collection (ATCC; P < .001; GLM/GEE test). The variation in phage infectivity was not due to the different levels of K1 CPS expression (P = .35; GLM/GEE test; Figure 1C ).
Infectivity of the Phage NTUH-K2044-K1-1 to a Capsule Deletion Mutant and an Extended-Spectrum β-Lactamase K1 Strain
Because this phage selectively infected strains with capsular type K1, we further examined whether capsule was essential for infection by this phage. We repeated the spot test using the NTUH-K2044 magA capsule deletion mutant [14, 28] . The magA deletion mutant was not infected by this phage, in contrast to the parental strain (data not shown). These results suggested that capsule was essential for infection by this phage, implying that it might be the receptor for this phage. An extended-spectrum β-lactamase (ESBL)-producing capsular type K1 strain isolated from NTUH was used to test the effect of antibiotic resistance on infection by the phage. The result indicated that phage infected the ESBL strain with capsular type K1 despite the presence of antibiotic resistance (data not shown).
Full Genome of the Phage NTUH-K2044-K1-1
The full genome of phage NTUH-K2044-K1-1 was 43 871 base pairs (bp) in length and was flanked with 234-bp direct-repeat sequences at the 2 ends. The phage-encoded proteins showed similarity with those of 2 phiKMV-like phages, Klebsiella phage KP34 (84% query coverage and 97% maximum identity; blastn alignment) and Vibrio phage VP93 (60% query coverage and 89% maximum identity; tblastx alignment) [22, 29] .
Annotation of the genome sequences showed that this phage was predicted to contain 35 open reading frames (ORFs) of >300 bp, all with the same orientation (Supplementary Table 2 ). In addition to sequence similarity, the NTUH-K2044-K1-1 Figure 2 . Predicted structural regions including endolysin putative coding sequences of the phages NTUH-K2044-K1-1, KP34, and VP93. Open reading frames (ORFs) are represented as arrows, and their predicted functions are indicated below the arrows; ORFs with significant sequence similarity are shown in the same color, and white ORFs are unique among these 3 phages.
phage exhibited synteny with phages KP34 and VP93 (Supplementary Table 2 and Figure 2) . The results of genome structure and sequence similarity all suggested classification of NTUH-K2044-K1-1 with the phiKMV-like viruses belonging to order Caudovirales, family Podoviridae.
Cloning and Expression of the Putative Capsule Depolymerase
Analysis of the ORFs of phage NTUH-K2044-K1-1 revealed that predicted ORF34 exhibited 27% amino acid identity (34/ 128) with a pectate lyase, suggesting that the protein might correspond to a capsule depolymerase. The K1-orf34 gene was cloned and expressed in E. coli. The purity of purified recombinant K1-ORF34 protein was shown in Figure 3A . On spotting to a plate inoculated with K. pneumoniae NTUH-K2044, the recombinant K1-ORF34 protein generated a translucent spot resembling the plaque halo ( Figure 3B ). The specificity of this enzyme was further examined in the 78 capsular type reference strains, and it was the same as that of the phage, suggesting that the K1-ORF34 protein is a K1 capsule depolymerase.
Application for Capsular Typing of the Capsule Depolymerase
Although the infectivity of phage differed (by up to 10 4 -fold) among capsular type K1 strains, spotting with aliquots of 100 ng or more of recombinant K1-ORF34 protein consistently revealed a translucent spot for each of these strains ( Figure 3C ). These results indicated that all 21 strains with capsular type K1 were sensitive to the K1-ORF34, suggesting that application of K1-ORF34 in capsular typing may provide a more consistent result than exposure to whole phage. and its K1-ORF34 protein (right) were spotted on the plate overlaid with top agar containing Klebsiella pneumoniae NTUH-K2044 strain. C, Activity of NTUH-K2044-K1-1 phage and purified K1-ORF34 protein among different capsular type K1 strains. Five K1 strains (NTUH-K2044, Canada PLA, A8126, ATCC35593, and A5054) and 1 K2 strain (A4528, which served as a negative control) were spotted with the phage NTUH-K2044-K1-1 (from 1 PFU to 10 7 PFUs) and K1-ORF34 protein (from 10 ng to 1500 ng). Different infectivity of the phage NTUH-K2044-K1-1 and consistent activity of the K1-ORF34 protein on the 5 K1 strains are observed.
Responses to Phage Inoculation in Mice
The phage might be applied for treatment of bacterial infections. First, we tested the safety of intraperitoneal inoculation with 1 × 10 8 PFUs of this phage in mice. The levels of IL-6 and TNF-α mRNA were induced in livers and spleens of mice at 1 and 3 hours after phage inoculation, respectively, and then rapidly declined ( Figure 4A and 4B). The inductions of IL-6 and TNF-α in serum were correlated with the expression profiles of IL-6 and TNF-α mRNA (data not shown). However, histological examination revealed no obvious disease in the livers, spleens, and brains of mice 24 hours after phage inoculation (Supplementary Figure) . This phage was detected in blood, spleen, liver, and brain 24 hours after phage inoculation ( Figure 4C ). The retention of the phage in spleen lasted for ≥72 hours after phage inoculation.
Treatment With Phage NTUH-K2044-K1-1 in Mice Infected With NTUH-K2044
The efficacy of treatment with the phage was evaluated in mice infected with NTUH-K2044. Intraperitoneal infection with 1.3 × 10 2 CFUs of NTUH-K2044 caused death in 75% (3/4) of mice.
In contrast, no deaths were observed among intraperitoneally infected mice treated with phage at 16 or 24 hours after infection ( Figure 5A ). Thus, treatment with this phage significantly increased the survival of mice infected with NTUH-K2044 (P = .02).
Retreatment With Phage NTUH-K2044-K1-1 in Mice Infected With NTUH-K2044
The efficacy of phage retreatment for infection was also evaluated in mice with 1 dose of phage preinoculation (inoculation before bacterial infection) ( Table 1) . Preinoculation of NTUH-K2044-K1-1 phage showed 100% and 50% protection rates at 10 days and 4 weeks, respectively. Phage could be recovered in killed mice even at 4 weeks. Preinoculation of a non-K1 phage revealed no protective effect. Therefore, existing phage rather than cytokine response seems to be the reason for protection. Repeated administration of the phage at 3 and 4 weeks still significantly increased the survival of mice infected with NTUH-K2044 (8/8 vs 9/16; P = .04).
Treatment With Phage NTUH-K2044-K1-1 in Mice With MR Imaging-Detected Abscess
Abscesses in the liver, kidney, or neck were detected with animal MR imaging in 11 mice after intragastric inoculation with 2 × 10 CFUs of NTUH-K2044. Eight of these mice were randomly selected for treatment with 1 × 10 9 PFUs of this phage per dose, administered twice daily for 2 weeks; the other 3 served as untreated controls. The phage treatment significantly prolonged the duration of survival in these mice (P = .005), although it did not significantly reduce overall study mortality ( Figure 5B ).
Treatment With K1-ORF34 Protein in Mice Infected With NTUH-K2044
Intraperitoneal infection with 3.3 × 10 3 CFUs of NTUH-K2044 resulted in death in 87.5% (7/8) of the mice, whereas all of the mice treated with K1-ORF34 protein (25 µg per mouse, administered intraperitoneally 30 minutes after infection) survived 6 CFUs of K. pneumoniae NTUH-K2044 strain, abscesses in the liver, kidney, or neck were detected in 11 mice by means of animal magnetic resonance imaging. Among them, 8 mice were randomly selected for intraperitoneal treatment with 1 × 10 9 PFUs of the NTUH-K2044-K1-1 phage twice daily for 2 weeks, and another 3 mice served as controls, without phage treatment. Phage treatment (P = .005; log-rank test) prolonged survival in these mice. C, Treatment efficacy of the K1-ORF34 in mice. Twelve 5-week-old female BALB/cByl mice were inoculated intraperitoneally with 3.3 × 10 3 CFUs of K. pneumoniae NTUH-K2044. After 30 minutes, the mice were either inoculated intraperitoneally with 25 µg of K1-ORF34 protein (4 mice) or not inoculated (8 mice). Treatment with purified K1-ORF34 (P = .006; log-rank test) increased the survival of mice infected with K. pneumoniae NTUH-K2044. through day 30 without significant clinical signs of illness (Figure 5C ). Thus, intraperitoneal treatment with purified K1-ORF34 significantly increased the survival rate in mice infected with NTUH-K2044 (P = .006).
Effects of Phage NTUH-K2044-K1-1 or K1-ORF34 Protein Treatment in Capsular Type K1 Strains With Variable Phage Infectivity
The effects of treatments with phage NTUH-K2044-K1-1 or K1-ORF34 protein in NTUH-K2044 and ATCC8045 (with lower phage infectivity) strains were compared in vitro. After treatment with phage (multiplicity of infection, 1000) for 30 minutes, 75% of NTUH-K2044 bacteria were killed and the survivors were all noncapsulated ( Figure 6A ). These bacteria showed transparent colonies and negative string test. Although the ATCC8045 bacteria were also significantly reduced by (61%), the killing effect of this phage in NTUH-K2044 was significantly higher than that in ATCC8045 (P = .03). Treatment with K1-ORF34 protein for 1 hour did not kill the NTUH-K2044 and ATCC8045 strains (data not shown). A previous study revealed that the capsule depolymerizing enzyme could sensitize the E. coli K1 strain to killing by the complement [30] . To determine whether the K1-ORF34 protein could sensitize the K. pneumoniae K1 strains to complement, the serum sensitivity of the enzyme-treated bacteria were analyzed. As shown in Figure 6B , the bacterial counts of NTUH-K2044 Figure 6 . A, Killing effect of phage NTUH-K2044-K1-1 among capsular type K1 strains. NTUH-K2044, ATCC8045 (with lower phage infectivity), and ΔmagA (an uninfected control) were incubated with the NTUH-K2044-K1-1 phage (multiplicity of infection, 1000). The survival bacterial counts after 30 minutes compared with initial counts were represented by the survival ratio from 3 independent experiments (mean ± standard deviation [SD]). B, Effect of treatment with K1-ORF34 protein in serum resistance. The bacteria (NTUH-K2044, ATCC8045, and ΔmagA [a serum-sensitive control]) or bacteria pretreated with the K1-ORF34 protein (enz-NTUH-K2044 and enz-ATCC8045) were mixed with serum from healthy human volunteers. The serum resistance was represented by the survival ratio from 3 independent experiments (mean ± SD). C, Effect of adding excess K1 CPS in increased serum susceptibility after treatment with K1-ORF34 protein. NTUH-K2044 alone, NTUH-K2044 pretreated with the K1-ORF34 protein (enz-NTUH-K2044), and NTUH-K2044 pretreated with the K1-ORF34 protein plus K1 CPS (enz-NTUH-K2044+K1 CPS) were mixed with serum from healthy human volunteers. The serum resistance was represented by survival ratio from 3 independent experiments (mean ± SD). D, Treatment efficacy of K1-ORF34 in 8 mice treated with cyclophosphamide (100 mg/kg, 5 days before infection) and inoculated intraperitoneally with 1.6 × 10 3 CFUs of Klebsiella pneumoniae NTUH-K2044. After 30 minutes of K. pneumoniae NTUH-K2044 infection, the mice were inoculated intraperitoneally with 25 µg of K1-ORF34 protein (4 mice) or not inoculated (4 mice). Treatment with purified K1-ORF34 (P = .007; log-rank test) increased the survival of cyclophosphamide-treated mice infected with K. pneumoniae NTUH-K2044.
and ATCC8045 increased after incubation with serum for 3 hours. Treatment with K1-ORF34 enzyme in NTUH-K2044 and ATCC8045 both significantly reduced the survival ratio in comparison with untreated bacteria (P < .001). There were no difference between the effect of enzyme treatment on the serum sensitivity of NTUH-K2044 and ATCC8045 strains (79% vs 89% reduction). The enhancement in complement killing of the K1-ORF34 protein was significantly blocked by adding an excess of K1 CPS (P = .01; Figure 6C ).
Because we demonstrated that the enzyme killed bacteria by removing the capsule and consequently increasing the bacterial sensitivity to host innate immunity, we then evaluated the treatment efficacy of the K1-ORF34 protein in cyclophosphamide-treated mice. The administration of cyclophosphamide significantly reduced the white blood cell counts (12.52 ± 0.62 vs 4.66 ± 0.79 × 10 3 cells/mm 3 ; P < .001) and increased the susceptibility to infection of NTUH-K2044. As shown in Figure 6D , intraperitoneal treatment with purified K1-ORF34 also significantly increased the survival of cyclophosphamide-treated mice with NTUH-K2044 infection (P = .007). Therefore, the suppressed immunity was still sufficient for clearance of the enzyme-treated bacteria.
DISCUSSION
Phages able to infect strains with capsular types K1 were isolated as early as 1940 [27, 31] , but their host spectra were not clearly determined, and no genomic sequences were available. Based on the specific host spectrum and complete genome sequences of the phage reported here, we expect that this phage and its proteins will be of great value for clinical applications and for comparison with other studies in the future. The survivors after phage treatment in vitro were observed to be noncapsulated. This result again demonstrated that capsule was essential for the infection of this phage, and also suggested that the capsule expression in bacterial population is not homogenous. These noncapsulated variants were not killed by this phage in vitro, but they could be easily cleared by our innate immunity. In spite of the importance of capsule in phage infection, the variable phage infectivity was not correlated with the amount of K1 CPS. The differential infectivity of this phage may reflect bacterial genome heterogeneity of strains isolated from Asian or Western patients, or of PLA-associated or nonassociated strains.
Emergence of ESBL and carbapenem resistance in K. pneumoniae is a significant problem globally [32] . At present, most of the strains causing community-acquired PLA remain susceptible to a wide range of antimicrobial agents [2, 33] . However, the occurrence of antibiotic-resistant PLA strains has been reported [34, 35] . Phage and phage-encoded proteins are potential tools for treatment of bacterial infections [36] [37] [38] , especially in patients whom antibiotic therapy has failed.
Although the induction of cytokines was detected, no significant disease or inflammatory sign was seen in mice tissues after inoculation with this phage. The production of neutralizing antibodies after administration of phages has been reported [39, 40] , but their effect in phage retreatment is unclear. The result of phage retreatment demonstrated that the phage was persistent even at 4 weeks. The persistence of phage again demonstrated that immune responses were not strong enough to clear phage efficiently. Moreover, phage with a long-term residence in tissues would improve the treatment efficacy [41] . Although the accurate efficacy of phage retreatment could be determined only after longer periods when prior phage was cleared, we found a significant protective effect of repeated administration with phage at 3 and 4 weeks. However, further clinical studies should be conducted to address the concerns about the efficacy of phage treatment for human patients who required retreatment.
Other studies have shown that immediate bacteriophage treatment was effective in murine models of K. pneumoniae burn wound, lobar pneumonia, and K2 PLA infections [36] [37] [38] 42] . The therapeutic efficacy of our phage in mice also was demonstrated, consistent with previous findings. To mimic the real treatment of K. pneumoniae infection, the efficacy of treatment with this phage was tested in mice harboring abscesses detected with MR imaging. Although the survival of mice was significantly prolonged with phage treatment, mortality rates were still high. Treatments were started only after the detection of focal lesions in mice with animal MR imaging (which seemed to be late in the disease process), timing that resulted in heavier bacterial burdens and more tissue destruction; as shown in Figure 5B , the untreated mice all died within 2 days after detection of abscesses. Unlike in humans, abscesses were relatively large in mice by the time they were detected with imaging. Therefore, we hypothesize that phage/enzyme treatment will be significantly more efficacious in humans, in whom earlier diagnosis is feasible.
Phage alone can kill bacteria, may amplify after targeting to the host, and seems to be a better treatment in immunocompromised hosts than depolymerase. The safety of phage administration in immunocompromised hosts has been documented elsewhere [40] . However, the whole phage genome usually contains many genes with unknown functions; to document its long-term safety is difficult. In contrast, depolymerase is a single protein, and its safety is easier to prove. Depolymerase can only remove the bacterial capsule, so host innate immunity is still required. Nevertheless, in our study, the cyclophosphamide-treated mice with decreased leukocytes were still able to clear the enzyme-treated bacteria. Previous studies found that cyclophosphamide did not reduce the level of serum complement, which was probably responsible for the protection regardless of decreased leukocytes [43, 44] .
In conclusion, we report here the isolation of a phage, NTUH-K2044-K1-1, and its capsule depolymerase exhibited specificity for capsular type K1. This phage and its capsule depolymerase are expected to find application for the detection and treatment of K. pneumoniae K1 strain, the major source of K. pneumoniae causing invasive infections.
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